- Visionary Ventures, an Aliso Viejo, California-based venture capital firm, closed Visionary Venture Fund II, at $114m
- The fund supported by existing and new Ophthalmology and Optometry Key Opinion Leader (KOL) limited partners
- Visionary Ventures is a venture capital firm that also invests in promising life sciences and ophthalmology startups
- Leading Visionary Fund II is Managing Partner, Jeffry Weinhuff and Principal, Garrett Hamontree along with Venture Partner Daniel Gil, PhD
- The firm is supported by industry leaders on the Investment Advisory Committee, including Richard Lindstrom, MD; Ehsan Sadri, MD; Farrell Tyson, MD; Bill Carpou; Robert Avery, MD; and Jeffry Weinhuff
- Fund II backed companies include Tarsus Pharmaceuticals, Orasis Pharmaceuticals, and TearClear. Past marquee Visionary investments include IanTech, RxSight, and Tear Film Innovations
Visionary Ventures: Closes Fund II, at $114M
